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Background. Nifurtimox has been used to treat Chagas disease for 40 years, but tolerance and safety data in
adults are scarce. We aimed to evaluate nifurtimox tolerance and safety in a cohort of Trypanosoma cruzi–infected
adult patients in a country of nonendemicity.
Methods. This observational study included all consecutive adults patients who were given a diagnosis of T.
cruzi infection from June through December 2008. Eligible patients received nifurtimox at 10 mg/kg/day for 60
days, with regular medical and biological follow-up. Adverse events (AEs) were recorded according to Common
Terminology Criteria for Adverse Events, version 3.0.
Results. Eighty-one patients received nifurtimox. Eight were lost to follow-up during treatment, and 41 (56.2%)
completed the 60-day course. All premature treatment terminations were caused by AEs; 97.5% of patients suffered
from AEs, mostly expected (90.5%) and not severe. Gastrointestinal symptoms predominated. Six (7.4%) patients
presented with a suspected unexpected serious adverse reaction: drug reaction with eosinophilia and systemic
symptoms ( ), Quincke edema ( ), acute myocarditis ( ), and anaphylaxis ( ). Patients withnp 3 np 1 np 1 np 1
3 or more AEs had an increased risk of premature treatment termination (hazard ratio, 8.42; 95% confidence
interval, 1.6–45.5).
Conclusion. Nifurtimox is poorly tolerated among adults with chronic Chagas disease, resulting in a low
treatment completion rate. Considering the significant risk of serious AEs, close monitoring is required, which
may be difficult to implement in poor rural areas of countries of endemicity. The safety and efficacy of nifurtimox
and benznidazole should be compared to improve current therapeutic recommendations, and pharmacovigilance
systems should be enhanced.
Chagas disease, a protozoan zoonosis caused by Try-
panosoma cruzi, is endemic in 21 North, Central, and
South American countries, where it affects 8–10 million
persons [1]. Its distribution is rapidly changing, as mil-
lions of person at risk have recently moved to areas of
nonendemicity in Europe, North America, Japan, and
the West Pacific region [2]. Most affected persons out-
side areas of endemicity are adults in the indeterminate
phase of the chronic stage [3]. A substantial proportion
of them are at risk of developing cardomyopathy, di-
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gestive megasyndromes, or both, with a potentially se-
vere outcome [4].
Until recently, treatment indications were restricted
to acute (including reactivation) and early latent in-
fections, with cure rates reaching 60%–90%, as assessed
by parasitological and immunological responses [4, 5].
Two recent studies of chronically infected adults showed
a reduction in the rate of progression toward advanced
cardiopathy in patients treated with antiparasitic drugs,
compared with untreated patients [6, 7]. The renewed
interest in parasite persistence as a pivotal mechanism
of chronic myocardial damage has also reinforced the
importance of eliminating T. cruzi [8, 9]. Recent con-
sensus treatment recommendations have therefore pro-
posed treatment for adults at the chronic stage, even
in the case of mild to moderate organ damage [10].
The expected benefits of antiparasitic treatment include
a reduction in the incidence of chronic complications
and a decrease in T. cruzi transmission, both congenital
and by blood or organ donation.
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Currently, 2 antiparasitic drugs are recommended for treat-
ing T. cruzi infection: nifurtimox and benznidazole. Nifurti-
mox, a 5-nitrofuran derivative, is also used in combination
with eflornithine to treat human African trypanosomiasis [11].
Because of the absence of strong scientific evidence, nifurtimox
treatment regimens vary among countries and authors. Today,
a 60-day course of 10 mg/kg/day is most frequently used, but
some recommendations propose a course of up to 120 days
[12]. Presently, nifurtimox efficacy data among different groups
of patients with different T. cruzi strains remain scarce [13, 14].
In addition, data on safety and tolerance profiles in adults are
still lacunar [13, 14]. Therefore, given that the evaluation of
the risk-benefit ratio cannot be based on sufficient evidence,
clinicians face difficulties in deciding whether to treat individual
patients [13]. This is preoccupying, because a high proportion
of T. cruzi–infected patients are eligible to receive treatment
according to recent recommendations [8, 10]. To provide evi-
dence and help strengthen guidelines, we aimed to describe the
tolerance and safety of nifurtimox in a cohort of adult patients
with chronic Chagas disease.
METHODS
Setting. This observational study was nested in a cohort study
of Chagas disease conducted among Latin American migrants
living in Geneva, Switzerland. It was conducted at the Geneva
University Hospitals from June 2008 through July 2009 [15].
Participants and procedures. Participants were 116 years
old and had been given a diagnosis of Chagas disease on the
basis of 2 positive serological test results (ELISA Cruzi [bio-
Me´rieux] and Bioelisa Chagas [Biokit]). All patients were con-
tacted by phone and invited to undergo medical evaluation to
determine the stage of disease, in accordance with a procedure
described elsewhere [15], and potential contraindications to
treatment. Patients eligible for treatment received extensive in-
formation and, on acceptance, were treated with nifurtimox
(Lampit; Corporacio´n Bonima, Bayer) at 10 mg/kg/day divided
into 3 doses for 60 days. Individual packages (100 tablets) were
given one by one at the initial and during follow-up visits.
Drugs were donated by the World Health Organization. Patients
received a document in Spanish or Portuguese describing the
daily dosage of nifurtimox, the dates of follow-up visits, and
the phone numbers of the physician in charge.
Absolute contraindications to nifurtimox were previous anti–
T. cruzi treatment, clinically significant psychiatric disorder (eg,
moderate to severe depression, severe anxiety, and psychosis),
peripheral neuropathy, epilepsy, pregnancy, hepatic or renal
failure, and inability to attend follow-up visits. Age 150 years
was a relative contraindication subject to case-by-case evalua-
tion. Follow-up visits included clinical and biological evalua-
tions (complete blood count, liver function tests, and deter-
mination of serum creatinine level) on days 7, 21, and 60. In
the case of suboptimal adherence, duration of treatment was
extended to make up for the missed pills. In the case of absence
at a follow-up visit, patients were contacted on their mobile
phones or by mail. Patients were encouraged to contact the
investigators in the case of a medical problem at any time
during the treatment course. When necessary, decisions re-
garding temporary or definitive treatment interruption were
made jointly with the investigators. The study was approved
by the Ethics Committee of the Geneva University Hospitals
in January 2008.
Data collection. At each visit, patients were questioned on
the occurrence of expected adverse reactions to nifurtimox (by
checklist). The investigators also recorded other (unexpected)
events spontaneously reported by the patients. Both expected
and unexpected adverse events (AEs) were recorded on a case
report form and graded according to Common Terminology
Criteria for Adverse Events, version 3 (2006). The timing of
occurrence and the duration of the event were also recorded
on the case report form. Suspected unexpected serious adverse
reactions (SUSARs) and serious AEs were reported to the na-
tional pharmacovigilance system. In the case of persistant symp-
toms reported at the end-of-treatment visit, follow-up was ex-
tended until the disappearance of symptoms. During the end-
of-treatment visit, adherence to treatment was assessed by count-
ing the remaining pills from the original packages given to the
patient. In the case of premature treatment interruption, count-
ing was compared with the expected pill consumption until the
day of interruption.
Statistical methods. Results were presented with means
and confidence intervals (CIs) or standard deviations for nor-
mally distributed variables or medians and interquartile ranges
for skewed variables. Continuous variables were compared with
the Student t test. Categorical variables were compared with x2
test or the Fisher exact test, as appropriate.
The risk of premature treatment termination with the num-
ber of days of treatment was analyzed by the Kaplan-Meier
method. Patients without an identified date of treatment ter-
mination ( ) were not included in the logistic and survivalnp 8
analyses. The number of AEs as a risk factor for premature
treatment termination was also analyzed using a time-depen-
dent Cox model. The significance level was .P ! .05
RESULTS
Of 130 patients with Chagas disease eligible to participate in
the study, 124 completed medical evaluation. Their sociode-
mographic and clinical characteristics are presented in Table 1.
All but one patient resided in Switzerland without a residency
permit or health insurance (undocumented). After medical
evaluation, 81 (65.3%) of 124 patients were deemed to be el-
igible for nifurtimox treatment (Table 1 and Figure 1).
AEs. A total of 535 AEs were recorded for 79 of the 81
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Table 1. Demographic and Clinical Characteristics of Trypan-
osoma cruzi–Infected Patients and Patients Treated with Nifur-
timox in Geneva, Switzerland
Characteristic
Patients with
T. cruzi infection
(n p 124)
Patients treated
with nifurtimox
(n p 81)
Female 107 (86.3) 66 (81.5)
Age, median years (range) 41 (17–70) 39 (17–58)
Bolivian 120 (96.8) 79 (97.5)
Disease stage
Indeterminate form 109 (87.9) 68 (84)
Cardiopathy 14 (11.3) 12 (14.8)
Digestive tract involvement 1 (0.8) 1 (1.2)
NOTE. Data are no. (%) of patients, unless otherwise indicated.
Figure 1. Flow diagram of the study participants.
patients. The 2 patients without AEs were lost to follow-up
early during the treatment course. Most AEs ( ; 90.5%)np 484
were expected, occurred early during the treatment course, and
were mild or moderate (Table 2). The majority of expected AEs
were digestive ( ; 35.1%), neurological ( ;np 170 np 133
27.5%), constitutional ( ; 20.7%), musculoskeletalnp 100
( ; 10.5%), or dermatological ( ; 6.8%). Unex-np 51 np 33
pected nonsevere AEs included fever ( ), loss of short-np 13
term memory ( ), dyspnea or tachypnea ( ), andnp 11 np 7
edema ( ). SUSARs occurred in 6 patients (7.4%): drugnp 6
reaction with eosinophilia and systemic symptoms (DRESS)
( ), acute myocarditis ( ), Quincke edema ( ),np 3 np 1 np 1
and grade 3 anaphylaxis reaction ( ) (Table 3). Nifurtimoxnp 1
was interrupted or terminated in the 6 patients with SUSARs,
and they recovered without sequelae.
Weight loss. Weight measurements were available before
and at completion of treatment in 62 patients. Fifty-two
(83.9%) patients lost weight during treatment; the mean loss
was 2.1 kg (95% CI, 1.6–2.6 kg).
Biological analysis. Hematological, liver, and renal func-
tion test results remained within normal ranges on days 7, 21,
and 60 of treatment in all patients, except in the 6 with SUSARs.
Adherence to treatment. Pill counting was possible in 48
(59.3%) of 81 patients. Full adherence to prescribed treatment
was found in 44 (92.1%) patients. Adherence was significantly
higher in patients who completed the 60-day treatment course
(97.6%) than in patients who terminated treatment before day
60 (78.6%) ( ).Pp .03
Treatment duration and causes of interruption. Among
the 81 patients who started treatment, 8 (9.9%) were lost to
follow-up. The date of treatment termination was not available
for these 8 patients, whose demographic and clinical charac-
teristics did not statistically differ from those of the 73 patients
with known treatment duration (data not shown). Thirty-two
(43.8%) of the 73 patients did not complete the full 60-day
treatment course (Table 4). On average, premature treatment
termination occurred on day 14 (95% CI, 10.2–17.8 days) (Fig-
ure 2) and was caused by AEs in all cases. The following AEs
were found to be associated with the risk of premature treat-
ment termination in the univariate analysis ( ): pruri-P ! .10
tus, asthenia, neuropathy, dyspnoea, headache, myalgia, and
rash. The risk significantly increased in the presence of 3 and
more of these AEs (hazard ratio [HR], 8.4; 95% CI, 1.6–
45.5; ) but not in presence of 1 AE (HR, 0.4; 95% CI,Pp .01
0.04–5.0; ) or 2 AEs (HR, 0.6; 95% CI, 0.1–7.3;Pp .51 Pp
). In addition, temporary treatment interruption and re-.72
duction of drug daily doses were common (28.8% and 17.8%,
respectively).
DISCUSSION
This study shows that nifurtimox treatment in adult Latin
American migrants infected with T. cruzi is poorly tolerated
and is associated with a significant risk of serious AEs. Nifur-
timox was administered at the usual dose and for the recom-
mended duration in ambulatory care. Only 56.2% patients
completed the full 60-day course, and 28.8% did not tolerate
treatment for 130 days. Although most AEs were graded as
mild or moderate, the majority of patients endured several AEs
concomittantly, which contributed to the high rate of prema-
ture treatment termination. A substantial proportion of patients
experienced treatment interruption or needed dose reduction
at some point. Most AEs occurred early during the treatment
course, suggesting that most AEs with nifurtimox do not de-
pend on cumulative doses. Digestive symptoms were the most
frequent, whereas neurological symptoms were the most per-
sistant. Because most AEs were mild in intensity, symptomatic
treatment was prescribed. When AEs were more severe, nifur-
timox dose was temporarily reduced or the drug was suspended
until the patient recovered with the appropriate treatment.
Even after 40 years of use, published data on nifurtimox
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Table 2. Description of Expected Adverse Events among 81 Trypanosoma cruzi–Infected Patients Treated with
Nifurtimox in Geneva, Switzerland
Adverse event
Frequency,
no. (%)
Grade of severity,a %
Time of onset,
median days (IQR)
Duration of illness,
median days (IQR)1 2 3 4
Gastrointestinal
Anorexia 59 (74.7) 89.8 10.2 0 0 9 (2–13) 42 (17.5–62.5)
Nausea 44 (54.3) 81.4 11.6 4.7 2.3 3 (1–9) 14 (3–47)
Abdominal pain 32 (39.5) 87.1 3.2 6.5 3.2 8.5 (2–18) 7 (2–15)
Vomiting 21 (25.9) 76.2 14.3 9.5 0 11 (3–29) 2 (1.5–16.5)
Diarrhea 14 (17.2) 85.7 7.2 0 7.1 11 (5.5–19.5) 3 (1–11)
Neurological
Headaches 59 (72.8) 69.5 23.7 6.8 0 4 (1–11) 13 (6–30)
Mood alteration 40 (49.4) 91.9 8.1 0 0 7 (2–23) 25 (17–58)
Dizziness 27 (33.3) 69.2 15.4 15.4 0 6 (1–12) 6 (25–12.5)
Sensitive neuropathy 4 (4.9) 100 0 0 0 44 (18–52) 26.50 (7.5- 52.5)
Constitutional
Fatigue 56 (69.1) 78.6 14.3 7.1 0 8 (2–15) 23 (8–51)
Insomnia 44 (54.3) 95.5 4.5 0 0 5 (2–20) 33 (11- 59)
Musculoskeletal
Arthralgia 27 (33.3) 84.6 7.7 7.7 0 11 (5.5–15.5) 4.5 (2–10)
Myalgia 24 (29.6) 75.0 16.7 8.3 0 11 (8–22) 5 (3–11)
Dermatological
Prurit 19 (23.5) 76.5 23.5 0 0 6 (3–17) 7.5 (2–23)
Rash 14 (17.2) 61.5 23.1 15.4 0 9 (5.5–13.5) 4 (1–6)
NOTE. IQR, interquartile range.
a Severity was graded from 1 (mild) to 5 (fatal), according to Common Terminology Criteria for Adverse Events, version 3.0.
safety and tolerance in adults are scarce. In Brazil, Coura et al
[14] reported a 29.9% rate of premature treatment termination
due to AEs among 27 adults treated with low-dose nifurtimox
(5 mg/kg/day) for 30 days. The most frequent AEs were di-
gestive, neurologic, and psychiatric. Levi et al [16] administered
nifurtimox at various doses (5–17 mg/kg/day) for up to 120
days in 8 patients and reported premature treatment termi-
nation in six (75%) patients because of severe AEs (nausea,
vomiting, weight loss, neuropathy, and psychiatric disturbance).
No data are available from other countries—in particular Bo-
livia, where benznidazole has been most frequently used. Some
investigators mention that tolerance to nifurtimox varies be-
tween ethnic and age groups and that children appear to tolerate
it better than adults [17, 18]. In our adult cohort, age was not
associated with premature treatment termination.
Of concern, six (7.4%) patients suffered from nonfatal SU-
SARs. DRESS, Quincke edema, myocarditis, and grade 3 an-
aphylaxis reactions are described in relation with nifurtimox
for the first time, to our knowledge. DRESS, which has been
described mostly with aromatic anticonvulsivants and sul-
phonamides, usually begins 2–6 weeks after treatment initiation
but may also occur after treatment discontinuation, which hap-
pened with one of our patients [21]. The case of myocarditis
occurred in a previously healthy young woman who did not
have previous evidence of chagasic chronic cardiopathy. In the
absence of a proven alternative etiology and endomyocardial
biopsy, direct myocardial nifurtimox toxicity was only consid-
ered as a possible cause. A possible explanation could be an
acute intramyocardial inflammatory reaction secondary to par-
asitic antigen release. More studies are needed to assess the
potential myocardial toxicity of nifurtimox in T. cruzi–infected
patients. Two patients with no history of allergy suffered from
severe allergic reactions (Quicke edema and grade 3 anaphy-
laxis) within the first 2 weeks of treatment. In the absence of
concomitant exposition to any other significant allergens, ni-
furtimox was considered the most probable cause of these re-
actions.
Rassi et al [22] reported the use of a combination of nifur-
timox and betametasone. Steroids were intended to increase T.
cruzi parasitemia and thus enhance nifurtimox efficacy. The
authors did not report better treatment tolerance in patients
receiving steroids. Therefore, considering the nonimmunoal-
lergic etiology of most AEs, we do not support the general use
of prophylactic corticosteroids to improve nifurtimox toler-
ance. The systematic addition of antihistaminic drugs to pre-
vent nifurtimox related AEs has not been evaluated, to our
knowledge.
When considering the high rate of transient or definitive
treatment interruption, the social condition of our patients
should probably be taken into account. Almost all were un-
Table 3. Description of Suspected Unexpected Serious Adverse Reactions (SUSARs) during Nifurtimox Treatment ( )np 6
Patient sex (age in years)—MH SUSAR Clinical description
Day of
onset Outcome
Female (27)—healthy, no allergy, no treatment Myocarditis Febrile chest pain, negative T waves, elevated se-
rum troponine I level, normal echocardiogram
and 24-h holter recording results, negative viral
serological and anti–nuclear factor results
10 Recovered with NSAIDs; second-line treatment
with benznidazole interrupted at day 3 because
of pruritic generalized maculopapular rash
Male (31)—healthy, no allergy, no treatment DRESS Febrile generalized maculopapular rash, adenopa-
thies, blood eosinophilia, elevated liver enzyme
levels, negative viral serological results
63a Recovered with high-dose OCS
Female (38)—known asthma, no allergy, no
treatment
DRESS Fever, severe pruritus, tachypnea, adenopathies,
blood eosinophilia
12 Recovered with high-dose OCS; definitive treat-
ment interruption
Female (38)—known chronic lumbar pain, no
allergy, no treatment
DRESS Fever, dyspnea, generalized maculopapular rash,
adenopathies (including mediastinal and hilar),
blood eosinophilia, elevated liver enzyme levels,
negative viral serological and anti–nuclear factor
results, pulmonary infiltrate
21 Recovered with high-dose OCS; definitive treat-
ment interruption
Female (39)—known gastritis, no allergy, in-
termittent esomeprazol treatment
Quincke edema Dyspnea, dysphonia, normal blood oxygen satura-
tion, vocal cord edema (laryngoscopy)
11 Recovered with high-dose OCS; completed 60-
day benznidazole course
Female (40)—healthy, no allergy, no treatment Anaphylaxis grade 3 Diffuse erythematous rash, dyspnea, dysphonia,
low blood pressure, normal chest radiography
and laryngoscopy results
9 Recovered with oral antihistaminics and intrave-
nous corticosteroids; definitive treatment
interruption
NOTE. DRESS, drug reaction with eosinophilia and systemic symptoms; MH, medical history; NSAIDs, nonstreroidal anti-inflammatory drugs; OCS, oral corticosteroids.
a Three days after treatment termination.
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Table 4. Observed Duration of Nifurtimox Treatment among
73 Patients with Trypanosoma cruzi Infection in Geneva,
Switzerland
Duration Patients, no. (%)
60 days 41 (56.2)
53 days (90% of recommended duration) 47 (64.4)
45 days (75% of recommended duration) 50 (68.4)
30 days (50% of recommended duration) 52 (71.2)
Figure 2. Kaplan-Meier curve for the occurrence of premature treatment termination among 73 Trypanosoma cruzi–infected patients treated with
nifurtimox in Geneva, Switzerland.
documented migrants living in Geneva with very low socio-
economic status and poor social support. Prior studies con-
ducted among this population showed that the constant stress
to earn a daily income resulted in frequent mental health prob-
lems and poor health perception [23]. Therefore, nifurtimox
tolerance may differ in this vulnerable population relative to
patients living in their home country with more social support.
Considering the current migration flows and the changing ep-
idemiology of Chagas disease, the influence of social determi-
nants on treatment tolerance deserves further investigations.
Most patients in our cohort were Bolivians, which may limit
the generalizability of our observations. At present, there is no
evidence for a genetic influence on tolerance to nifurtimox,
despite suggestions that tolerance in Central and South America
may differ [17]. This important topic should be further studied,
because it may eventually lead to distinct pharmacological rec-
ommendations. Nevertheless, Bolivians are the most affected
by Chagas disease, and several countries outside Latin America
harbor large communities of Bolivian migrants [2]. In fact,
most published cases of Chagas disease outside the Americas
occurred in Bolivian migrants [3, 13, 15].
Our results call into question the safety of large-scale use of
nifurtimox among adult patients in settings with difficult access
to medical care, such as poor rural areas of South America.
Treatment risks and benefits should be thoroughly discussed
with patients before initiation. Easily accessible medical care
and close clinical follow-up appear to be prerequisite to ni-
furtimox treatment. In addition, patients should be educated
regarding identification of early symptoms of serious AEs. To
further define nifurtimox tolerance in different settings, all rel-
evant AEs should be reported to pharmacovigilance systems.
Pharmacovigilance for nifurtimox and benznidazole in Europe
is currently not sufficient and should be enhanced to collect
appropriate and extensive safety data.
It is not known weather benznidazole is better tolerated than
nifurtimox in adult T. cruzi–infected patients, because the 2
drugs have not been properly compared. In a retrospective
study conducted among 1047 adults treated with benznidazole
for 30 days, Viotti et al [19] reported a 17.2% rate of premature
treatment termination caused by AEs. A higher rate (27%) was
reported among 11 patients receiving benznidazole for a longer
period (60 days) [20]. Cutaneous, hematological, or neurolog-
ical AEs are frequent and may be life-threatening [24]. Con-
sidering the lack of current therapeutic alternatives, a clinical
trial comparing the safety and efficacy of benznidazole and
nifurtimox is needed to foster better evidence-based therapeu-
tic recommendations.
Because 70% of our patients achieved at least 30 days of
treatment, the clinical (ie, incidence of T. cruzi–related organ
damage) and parasitological efficacy of a 30-day nifurtimox
regimen could be evaluated. However, this treatment duration
is unlikely to lead to a significant decrease in serious AEs,
because the majority occur during the first month of treatment.
Other potential strategies to improve nifurtimox tolerance in-
clude prolonged treatment with a reduced daily dose, an al-
ternate-day regimen, or combination therapy with other try-
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panocidal drugs (eg, benznidazole) to reduce dose and/or
duration [12, 13]. The ongoing development of new drugs for
this neglected tropical disease provides some hope [25, 26].
More than a century after Carlos Chagas’ discovery, patients
and clinicians still await an efficient, safe, and accessible drug.
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